Complix Enters into Strategic Collaboration with MSD to Develop Cell-Penetrating Alphabodies to Treat Cancer.
Complix to receive upfront fees, research funding, and milestone payments.

Hasselt, Belgium, January 6 2016 - Complix, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™, for the treatment of cancer and severe autoimmune diseases, announced it has entered into a strategic drug discovery collaboration with Merck & Co., Inc. (known as 'MSD' or 'Merck' (in the United States and Canada)) through its subsidiary, Merck Sharp & Dohme Corp., to develop Cell-Penetrating Alphabodies (CPABs) for the treatment of cancer.

GIMV NV issued this content on 2016-01-06 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-06 16:49:13 UTC

Original Document: http://www.gimv.com/en/media-and-news/press-releases/complix-enters-into-strategic-collaboration-with-msd-to-develop-cell-penetrating-alphabodies-to-treat-cancer